[肺大细胞神经内分泌癌分子生物标志物的研究进展]
[Advances in Molecular Biomarker for Pulmonary Large Cell Neuroendocrine Carcinoma].
作者信息
Zhang Jinyao, Yang Lin, Li Junling
机构信息
Department of Medical Oncology, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Pathology, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2020 Nov 20;23(11):983-988. doi: 10.3779/j.issn.1009-3419.2020.101.46.
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a pathological subtype of lung neuroendocrine cancer, which accounts for 2.4%-3.1% in surgical specimens of lung cancer. It is characterized by high invasiveness and poor prognosis, and highly correlated with smoking. There are few relevant studies due to the low incidence and small sample size. Therefore, it is relatively difficult to diagnosis and treatment in clinical practice. In this review, we described molecular subtype, diagnostic and prognostic-related markers about large cell neuroendocrine carcinoma of lung based on the recent progress in genomic sequencing and molecular markers, to find the direction for the next research. .
肺大细胞神经内分泌癌（LCNEC）是肺神经内分泌癌的一种病理亚型，在肺癌手术标本中占2.4%-3.1%。其特点是侵袭性高、预后差，且与吸烟高度相关。由于发病率低、样本量小，相关研究较少。因此，临床实践中的诊断和治疗相对困难。在本综述中，我们基于基因组测序和分子标志物的最新进展，描述了肺大细胞神经内分泌癌的分子亚型、诊断和预后相关标志物，以寻找下一步研究的方向。
Zotero 插件